OmniAb, Inc. reported second quarter 2026 financial results on August 6, 2026, announcing a significant increase in revenue driven by milestone payments and new partner programs. Second-quarter revenue reached $13.4 million compared to $3.9 million in the prior-year period, resulting in a net loss of $5.9 million or $0.05 per share, an improvement from the $15.9 million loss recorded previously. The company raised its full-year 2026 revenue guidance to $32–$36 million and updated its cash outlook, citing strong momentum with 110 active partners and 425 active programs. Key business highlights included new license agreements with EnRosa Therapeutics and argenx, and clinical advancements for partner candidates such as Merck KGaA’s precemtabart tocentecan advancing to Phase 3 and Teva’s TEV-’408 moving into Phase 2b development. OmniAb operates in the biotechnology sector, providing discovery research technology and antibody screening platforms to enable the development of next-generation therapeutics.

OmniAb, Inc. appointed Amechi Nwachuku as Chief Operating Officer, effective July 13, 2026. Mr. Nwachuku, a former Vice President at Thermo Fisher Scientific, will receive an initial annual base salary of $445,000 and a $20,000 signing bonus. He is eligible for an annual target bonus of 45% of his base salary. Additionally, effective August 1, 2026, the company granted him stock options to purchase 800,000 shares of common stock under the 2022 Incentive Award Plan. OmniAb, Inc. is a biotechnology company that provides antibody discovery technologies.